The value of lipase, lipoprotein (a) and lipoprotein-associated phospholipase A2 in the diagnosis of early cardiovascular injury in patients with non-alcoholic fatty liver disease

Abstract

Abstract: Objective To investigate the correlation of lipase, lipoprotein (A) and lipoprotein-associated phospholipase A2 with early cardiovascular injury in patients with non-alcoholic fatty liver disease (NAFLD). Methods A total of 100 NAFLD patients (study group) and 100 healthy subjects (control group) were collected. Their general data and laboratory indicators were compared and the correlation between the indexes of the study group and the NAFLD group were studied. At the same time, the diagnostic efficacy of a combined detection with three indicators in the diagnosis of early cardiovascular injury in NAFLD was analyzed. Results The levels of lipase (50.58±11.52 mmol/L), lipoprotein (a) (93.50±32.57 mmol/L), and lipoprotein-associated phospholipase A2 (551.15±67.47 mmol/L) in the study group were significantly higher than those in the control group, with statistically significant differences (P<0.05). Logistic multivariate regression analysis showed that gender, age, hypertension, and diabetes were not associated with NAFLD, while lipase (β=11.25, P=0.02), lipoprotein (a) (β=9.56, P=0.01), and lipoprotein-associated phospholipase A2 (β=13.46, P=0.00) were all significantly associated with NAFLD, and lipoprotein-associated phospholipase A2 having the highest correlation coefficient. The combined detection of lipase, lipoprotein (a), and lipoprotein-associated phospholipase A2 showed a sensitivity of 82.33%, an accuracy of 64.27%, and an AUC of 0.725 for the diagnosis of NAFLD-related cardiovascular injury, which was significantly higher than that of individual detection, with statistically significant differences (P<0.05). Conclusion Lipase, lipoprotein (A) and lipoprotein-associated phospholipase A2 are independent risk factors for NAFLD. A combined detection of these three is more valuable in evaluating NAFLD lesions.

Key words: Non-alcoholic fatty liver disease, Lipase, Lipoprotein (a) , Lipoprotein-associated phospholipase A2

YANG Sen, WU Chun-fang, ZHANG Yang-yang, CHENG Si, SHI Lei, WANG Li-li. The value of lipase, lipoprotein (a) and lipoprotein-associated phospholipase A2 in the diagnosis of early cardiovascular injury in patients with non-alcoholic fatty liver disease[J]. Chinese Hepatolgy, 2025, 30(9): 1200-1203.

References

[1] Xin Z, Zhu Y, Wang S ,et al. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score[J]. Liver Int,2020,40(4):806-814.
[2] Harada P H, Bensenõr I J M, Drager L F, et al. Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil[J]. Atherosclerosis,2019,284(5):59-65.
[3] Koo B K, Allison M A, Criqui M H, et al. The association between liver fat and systemic calcified atherosclerosis[J]. J Vasc Surg,2020 ,71(1):204-211.
[4] Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M ,et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events[J]. Hepatol Commun,2018,2(7):798-806.
[5] Lauridsen B K, Stender S, Kristensen T S, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279013 individuals[J]. Eur Heart J,2018,39(5):385-393.
[6] Unalp-Arida A, Ruhl C E. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population[J]. Hepatology,2020,71(3):820-834.
[7] Grimaudo S, Pipitone R M, Pennisi G, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2020,18(4):935-944.
[8] Haas J T, Vonghia L, Mogilenko D A ,et al. Author correction: transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution[J]. Nat Metab,2019,1(6):604-614.
[9] Gehrke N, Schattenberg J M. Metabolic inflammation-A role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease[J].Gastroenterology,2020,158(7):1929-1947.
[10] Langsted A, Madsen C M, Nordestgaard B G. Contribution of remnant cholesterol to cardiovascular risk[J]. J Intern Med,2020,288(1):116-127
[11] Chen Y Q, Pottanat T G, Siegel R W ,et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids[J]. J Lipid Res,2020,61(8):1203-1220
[12] Barchetta I, Cimini F A, Chiappetta C ,et al. Relationship between hepatic and systemic angiopoietin-like 3, hepatic vitamin D receptor expression and NAFLD in obesity[J]. Liver Int,2020,40(9):2139-2147
[13] Saeed N, Nadeau B, Shannon C, et al. Evaluation of dietary approaches for the treatment of non-alcoholic fatty liver disease: a systematic review[J]. Nutrients,2019,11(12):3064
[14] Luukkonen P K, Dufour S, Lyu K ,et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease[J]. Proc Natl Acad Sci USA,2020,117(13):7347-7354.
[15] Patel K, Harrison S A, Elkhashab M ,et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial[J]. Hepatology,2020,72(1):58-71.
[16] Bricambert J, Alves-Guerra M C, Esteves P ,et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity[J]. Nat Commun,2018,29,9(1):2092.
[17] Kim C W, Addy C, Kusunoki J ,et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation[J].Cell Metab,2017,26(2):394-406.